SANN Statistics

Total Valuation

Santhera Pharmaceuticals Holding AG has a market cap or net worth of CHF 96.85 million. The enterprise value is 106.73 million.

Market Cap	96.85M
Enterprise Value	106.73M

Important Dates

The next estimated earnings date is Thursday, December 12, 2024.

Earnings Date	Dec 12, 2024
Ex-Dividend Date	n/a

Share Statistics

Santhera Pharmaceuticals Holding AG has 12.11 million shares outstanding. The number of shares has increased by 24.61% in one year.

Current Share Class	n/a
Shares Outstanding	12.11M
Shares Change (YoY)	+24.61%
Shares Change (QoQ)	+6.07%
Owned by Insiders (%)	0.46%
Owned by Institutions (%)	10.04%
Float	9.05M

Valuation Ratios

The trailing PE ratio is 1.40.

PE Ratio	1.40
Forward PE	n/a
PS Ratio	0.75
PB Ratio	1.95
P/TBV Ratio	n/a
P/FCF Ratio	2.05
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 1.85, with an EV/FCF ratio of 2.26.

EV / Earnings	1.70
EV / Sales	0.94
EV / EBITDA	1.85
EV / EBIT	1.99
EV / FCF	2.26

Financial Position

The company has a current ratio of 0.63, with a Debt / Equity ratio of 0.55.

Current Ratio	0.63
Quick Ratio	0.51
Debt / Equity	0.55
Debt / EBITDA	0.46
Debt / FCF	0.56
Interest Coverage	3.10

Financial Efficiency

Return on equity (ROE) is 2,374.13% and return on invested capital (ROIC) is 91.78%.

Return on Equity (ROE)	2,374.13%
Return on Assets (ROA)	39.20%
Return on Capital (ROIC)	91.78%
Revenue Per Employee	2.52M
Profits Per Employee	1.40M
Employee Count	45
Asset Turnover	1.33
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -17.79% in the last 52 weeks. The beta is 0.12, so Santhera Pharmaceuticals Holding AG's price volatility has been lower than the market average.

Beta (5Y)	0.12
52-Week Price Change	-17.79%
50-Day Moving Average	8.89
200-Day Moving Average	9.27
Relative Strength Index (RSI)	39.90
Average Volume (20 Days)	12,847

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Santhera Pharmaceuticals Holding AG had revenue of CHF 113.59 million and earned 62.86 million in profits. Earnings per share was 5.70.

Revenue	113.59M
Gross Profit	107.07M
Operating Income	53.73M
Pretax Income	63.15M
Net Income	62.86M
EBITDA	57.27M
EBIT	53.73M
Earnings Per Share (EPS)	5.70

Full Income Statement

Balance Sheet

The company has 16.49 million in cash and 26.37 million in debt, giving a net cash position of -9.88 million or -0.82 per share.

Cash & Cash Equivalents	16.49M
Total Debt	26.37M
Net Cash	-9.88M
Net Cash Per Share	-0.82
Equity (Book Value)	48.06M
Book Value Per Share	4.11
Working Capital	-19.41M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 47.35 million and capital expenditures -162,000, giving a free cash flow of 47.18 million.

Operating Cash Flow	47.35M
Capital Expenditures	-162,000
Free Cash Flow	47.18M
FCF Per Share	3.90

Full Cash Flow Statement

Margins

Gross margin is 94.26%, with operating and profit margins of 47.30% and 55.34%.

Gross Margin	94.26%
Operating Margin	47.30%
Pretax Margin	55.60%
Profit Margin	55.34%
EBITDA Margin	50.42%
EBIT Margin	47.30%
FCF Margin	41.54%

Dividends & Yields

Santhera Pharmaceuticals Holding AG does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-24.61%
Shareholder Yield	-24.61%
Earnings Yield	71.29%
FCF Yield	48.72%

Stock Splits

The last stock split was on July 3, 2023. It was a reverse split with a ratio of 0.1.

Last Split Date	Jul 3, 2023
Split Type	Reverse
Split Ratio	0.1

Scores

Santhera Pharmaceuticals Holding AG has an Altman Z-Score of -4.18. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-4.18
Piotroski F-Score	n/a